FDA Approved: CALQUENCE — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

FDA approves a supplemental application for CALQUENCE (acalabrutinib) submitted by AstraZeneca Pharmaceuticals LP.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)

Snippet

SUPPL AP for CALQUENCE (ACALABRUTINIB)